Mursla Bio joins leading European consortium to advance clinical applications based on extracellular vesicle science

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk patients through the power of dynamic biopsy technology, announced it has been invited to join EVEREST, a leading European consortium.

‘We simply cannot sustain’: Idorsia weighs layoffs, deals, pipeline trims to bring cost down

Idorsia could cut “up to 500 positions” in R&D and associated support functions as the Swiss drugmaker finds ways to save cash until it can

July 22, 2023

LYL-845 by Lyell Immunopharma for Metastatic Melanoma: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

December 26, 2023

CMS Allows State to Offer Medicaid Incentive for Hospitals to Erase Patient Debt

The Centers for Medicare & Medicaid Services (CMS) signed off on a proposal by North Carolina Gov. Roy Cooper’s administration to offer scores of hospitals

July 31, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.